2026 Nobel Chemistry Prize: ⚗️ Tiny Tilt, Giant Shift: How Chemistry Chooses a Side
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🏆🧬 Tiny Tilt, Giant Shift: How Chemistry Chooses a Side Why does life favor one molecular “hand”? The 2026 Chemistry Nobel honors Henri Kagan and Kenso Soai for showing how tiny chiral imbalances can become dramatically amplified. ⚗️ In Soai’s landmark experiment, just 2% enantiomeric excess became 87%—and later autocatalytic reactions reached 99.99%. 💊 Why physicians should care: stereochemistry can determine whether a drug works at all—think L-DOPA. A tiny molecular bias can become biological destiny. 🔬✨
info_outline
🛡️ Beyond Cholesterol: GIMAP6, Vascular Defense & Atherosclerosis
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧬 Can atherosclerosis become lethal even without high cholesterol? A fascinating Cell study identifies GIMAP6 as an immune–vascular safeguard. Loss of GIMAP6 disrupts endothelial integrity and activates a mitoROS → PPARγ → CD36 pathway, driving macrophage lipid uptake, foam cells, inflammation, atherosclerosis, MI and heart failure—even without hyperlipidemia. ❤️ Human hypomorphic GIMAP6 variants also tracked with premature cardiovascular disease. 💡 Take-home: LDL matters enormously—but susceptibility within the vessel wall matters too.
info_outline
Beyond Breast Cancer 🩻❤️: When a Mammogram Warns the Heart
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🩻 Could a mammogram also offer a window into cardiovascular risk? ❤️ Breast arterial calcification (BAC), once largely dismissed as incidental, is increasingly recognized as a cardiovascular risk signal. Greater BAC burden has been associated with adverse outcomes, including stroke and heart failure. Maryland now requires BAC notification on routine mammograms. 💡 The practical message: see BAC → think cardiovascular risk assessment. ⚠️ But BAC ≠ coronary artery calcium, and we still lack randomized evidence that BAC-directed intervention improves outcomes. Perhaps the...
info_outline
🌿➡️🧠 From Algae to the Brain: Optogenetics Wins the 2026 Nobel
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🏆💡 From algae to the brain—a Nobel journey! The 2026 Nobel Prize in Physiology or Medicine honors Karl Deisseroth, Peter Hegemann & Georg Nagel for discoveries involving light-gated ion channels and optogenetics. 🌿 Channelrhodopsin in algae ➡️ 💡 Blue light opens the channel ➡️ ⚡ Ions flow ➡️ 🧠 Neurons can be precisely controlled Optogenetics gave neuroscience something extraordinary: the ability to manipulate defined neural circuits with remarkable temporal precision. Algae → Light → Ions → Neurons. Sometimes transformative science begins in unexpected...
info_outline
💊 Great Doctors Series: Paracelsus—When Poison Becomes Medicine & the Birth of Toxicology
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
☠️ Only the dose makes the poison. Meet Paracelsus (1493–1541)—physician, alchemist, provocateur, and a father of toxicology. ⚗️ He challenged Galen and Avicenna, championed observation over unquestioned authority, brought chemistry and minerals into therapeutics, studied miners’ diseases, and emphasized cleaner wound care. 🩺 His most enduring insight was beautifully simple: toxicity depends on dose. 💊 🎙️ Great Doctors Series: Paracelsus—The Dose, the Poison & the Revolution Where Curiosity Meets Clarity!
info_outline
Missed by Stockholm, Remembered by Science magazine
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🏅 Six breakthroughs. Zero Nobels. Medicine transformed. Why do some discoveries that fundamentally reshape biology never receive science’s most famous prize? 🧬🧠 From Avery showing that DNA carries hereditary information, to Milner redefining memory, Till & McCulloch establishing stem cells, Pawson decoding cell signaling, Barres revealing the active biology of glia, and the Human Genome Project—these are discoveries whose influence far exceeds any medal. 🔬 💡 Great science doesn’t need Stockholm’s stamp to change the world. Six biology breakthroughs that should have...
info_outline
Survodutide Strikes Twice: Weight Down, Glycemia Down 📉
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
info_outline
🔥 The 25% Effect: Retatrutide Redefines Weight Loss
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
In TRIUMPH-1, once-weekly retatrutide produced mean weight loss of up to 25% at 80 weeks—but the story extends beyond the scale. ⚖️ 🦵 Less knee osteoarthritis pain 😴 Fewer obstructive sleep apnea events ❤️ Improved cardiometabolic measures 🩸 89–93% with prediabetes reverted to normoglycemia A triple GIP/GLP-1/glucagon receptor agonist may reshape how we think about obesity: not simply kilograms lost, but disease burden reduced. 💡 ⚠️ Gastrointestinal adverse effects remain important.
info_outline
Eat More, Eat Less, Live Better 🍎❤️: The 2026 ACC Guide to Cardiovascular Nutrition
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🥗 Can we eat our way to a healthier heart? ❤️ The 2026 ACC Scientific Statement shifts the conversation from isolated nutrients to foods, dietary patterns, and degree of processing. 🌱 The message is remarkably practical: eat more vegetables, fruits, legumes, whole grains, nuts, seeds and healthy unsaturated fats; eat less ultra-processed food, refined grains, sugary drinks, processed meats and excess sodium. 🫒 Mediterranean and DASH patterns remain center stage. 🎙️ Dr RR Baliga’s Podkast for the Kurious Doc — Where Curiosity Meets Clarity!
info_outline
🧬 One Mutation, Massive Risk: EGFR T790M and Inherited Lung Cancer
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧬 Rare Variant, Real Risk: EGFR T790M and Lung Cancer Can lung cancer risk be inherited—even in never-smokers? 🫁🚭 In >3.3 million individuals, germline EGFR T790M was rare (~1 in 15,850) but strongly associated with lung cancer (OR 25.18). The association was particularly striking among never-smokers, and the variant showed remarkable lung-cancer specificity. A Southern Appalachian founder effect also revealed how genes, geography & history can converge on modern disease risk. 🗺️🧬 💡 A compelling case for refining genetic risk assessment and future targeted...
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.